Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Should You Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $12.56, but opened at $13.36. Fresenius SE & Co. shares last traded at $12.9075, with a volume of 13,854 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on FSNUY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Fresenius SE & Co. Stock Performance

The company’s 50-day moving average price is $12.95 and its 200 day moving average price is $12.35. The stock has a market capitalization of $28.57 billion, a PE ratio of 12.99 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The company had revenue of $6.91 billion during the quarter, compared to analysts’ expectations of $6.65 billion. On average, equities research analysts expect that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.